Log In
Print this Print this

Stribild, elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (formerly Quad)

  Manage Alerts
Collapse Summary General Information
Company Gilead Sciences Inc.
DescriptionFixed-dose combination tablet containing 150 mg cobicistat and 150 mg elvitegravir plus Truvada 200 mg emtricitabine/300 mg tenofovir
Molecular Target
Mechanism of ActionHIV integrase inhibitor; HIV reverse transcriptase inhibitor; Cytochrome P450 3A (CYP3A) inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV-1 infected antiretroviral treatment-naïve adults; Treat HIV-1 infection
Regulatory Designation
Partner Japan Tobacco Inc.; Mylan N.V.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today